A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas

Sponsor
University Health Network, Toronto
Study ID
NCT07014137
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ABSK043 single agent — DRUG
    ABSK043 BID continuously for 28 day cycle

Study Details

ABSK043 is a new type of experimental drug that blocks a protein called programmed cell death ligand 1 (PD-L1), which is important in controlling the body's response to harmful substances including cancer cells. By blocking PD-L1 from working, ABSK043 may allow the body's immune system to recognize and kill cancer cells. ABSK043 is considered "experimental" because it has not been approved for sale by Health Canada. Health Canada has approved the study drug to be administered in this research study. The main purposes of this study are: * To see if patients with your type of cancer benefit from ABSK043. * To evaluate the safety and tolerability of ABSK043. * To identify biomarkers (Biological flags used to measure disease progress or drug effect.) in tumor tissues or blood that might help identify patients whose cancers respond to ABSK043, and which patients may develop side effects from these study drugs. Examples of biomarkers include the type of white blood cells in your tumor or proteins in your blood. It is anticipated that about 20 people will take part in this study from the Princess Margaret Cancer Centre.

Key Dates

First listed
Jun 10, 2025
Start date
Sep 9, 2025
Status verified
Jun 2026
Primary completion
Mar 2, 2027
Completion
Mar 2, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: open label - Anti-PD-L1 (ABSK043)

Primary Outcome Measure

overall response rate of ABSK043 therapy in angiogenic sarcomas (i.e. intimal, head/neck angiosarcoma, and EHE) [ Time Frame: through study completion, an average of 1 year ]

Central Contacts

Related Studies